Merck & Co.

FDA
Pharma

FDA challenges broad use of PD-1 drugs in stomach cancer

The FDA is considering a class-wide action against PD-1 inhibitors in stomach cancer and esophageal cancer based on findings from multiple trials.
Angus Liu Sep 24, 2024 2:30pm
Asia

Daiichi, Eisai, Granules—Fierce Pharma Asia

Sep 20, 2024 10:16am
Keytruda

Merck's Keytruda helps early-stage TNBC patients live longer

Sep 15, 2024 8:10am
liver

Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype

Sep 14, 2024 10:30am
boxing punch blow hit punching bag fight

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study

Sep 8, 2024 11:30am
dart board miss failure

Merck’s Keytruda flunks pivotal studies in lung and skin cancers

Aug 29, 2024 10:16am